- Home
- ALVR vs CKPT Comparison
ALVR vs CKPT Comparison
Compare ALVR & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- CKPT
- Stock Information
- Founded
- ALVR 2013
- CKPT 2014
- Country
- ALVR United States
- CKPT United States
- Employees
- ALVR N/A
- CKPT N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- ALVR Health Care
- CKPT Health Care
- Exchange
- ALVR Nasdaq
- CKPT Nasdaq
- Market Cap
- ALVR 87.7M
- CKPT N/A
- IPO Year
- ALVR 2020
- CKPT 2017
- Fundamental
- Price
- ALVR $0.94
- CKPT $3.77
- Analyst Decision
- ALVR Sell
- CKPT Strong Buy
- Analyst Count
- ALVR 5
- CKPT 2
- Target Price
- ALVR $1.00
- CKPT $12.00
- AVG Volume (30 Days)
- ALVR 155.6K
- CKPT 946.5K
- Earning Date
- ALVR 11-04-2024
- CKPT 11-11-2024
- Dividend Yield
- ALVR N/A
- CKPT N/A
- EPS Growth
- ALVR N/A
- CKPT N/A
- EPS
- ALVR N/A
- CKPT N/A
- Revenue
- ALVR N/A
- CKPT $78,000.00
- Revenue This Year
- ALVR N/A
- CKPT N/A
- Revenue Next Year
- ALVR N/A
- CKPT $151,162.55
- P/E Ratio
- ALVR N/A
- CKPT N/A
- Revenue Growth
- ALVR N/A
- CKPT N/A
- 52 Week Low
- ALVR $0.58
- CKPT $1.36
- 52 Week High
- ALVR $2.49
- CKPT $3.95
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- CKPT 84.67
- Support Level
- ALVR $0.74
- CKPT $2.37
- Resistance Level
- ALVR $0.91
- CKPT $2.54
- Average True Range (ATR)
- ALVR 0.06
- CKPT 0.27
- MACD
- ALVR 0.01
- CKPT 0.10
- Stochastic Oscillator
- ALVR 94.50
- CKPT 88.60
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.